691 related articles for article (PubMed ID: 22327175)
1. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
3. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.
Huang H; Lai JY; Do J; Liu D; Li L; Del Rosario J; Doppalapudi VR; Pirie-Shepherd S; Levin N; Bradshaw C; Woodnutt G; Lappe R; Bhat A
Clin Cancer Res; 2011 Mar; 17(5):1001-11. PubMed ID: 21233403
[TBL] [Abstract][Full Text] [Related]
4. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Oliner J; Min H; Leal J; Yu D; Rao S; You E; Tang X; Kim H; Meyer S; Han SJ; Hawkins N; Rosenfeld R; Davy E; Graham K; Jacobsen F; Stevenson S; Ho J; Chen Q; Hartmann T; Michaels M; Kelley M; Li L; Sitney K; Martin F; Sun JR; Zhang N; Lu J; Estrada J; Kumar R; Coxon A; Kaufman S; Pretorius J; Scully S; Cattley R; Payton M; Coats S; Nguyen L; Desilva B; Ndifor A; Hayward I; Radinsky R; Boone T; Kendall R
Cancer Cell; 2004 Nov; 6(5):507-16. PubMed ID: 15542434
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
Sarraf-Yazdi S; Mi J; Moeller BJ; Niu X; White RR; Kontos CD; Sullenger BA; Dewhirst MW; Clary BM
J Surg Res; 2008 May; 146(1):16-23. PubMed ID: 17950331
[TBL] [Abstract][Full Text] [Related]
7. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
9. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.
Brown JL; Cao ZA; Pinzon-Ortiz M; Kendrew J; Reimer C; Wen S; Zhou JQ; Tabrizi M; Emery S; McDermott B; Pablo L; McCoon P; Bedian V; Blakey DC
Mol Cancer Ther; 2010 Jan; 9(1):145-56. PubMed ID: 20053776
[TBL] [Abstract][Full Text] [Related]
10. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.
Daly C; Eichten A; Castanaro C; Pasnikowski E; Adler A; Lalani AS; Papadopoulos N; Kyle AH; Minchinton AI; Yancopoulos GD; Thurston G
Cancer Res; 2013 Jan; 73(1):108-18. PubMed ID: 23149917
[TBL] [Abstract][Full Text] [Related]
12. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.
Molnar N; Siemann DW
Microvasc Res; 2012 May; 83(3):290-7. PubMed ID: 22387475
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
15. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
Hyman DM; Rizvi N; Natale R; Armstrong DK; Birrer M; Recht L; Dotan E; Makker V; Kaley T; Kuruvilla D; Gribbin M; McDevitt J; Lai DW; Dar M
Clin Cancer Res; 2018 Jun; 24(12):2749-2757. PubMed ID: 29559563
[No Abstract] [Full Text] [Related]
19. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.
Holopainen T; Saharinen P; D'Amico G; Lampinen A; Eklund L; Sormunen R; Anisimov A; Zarkada G; Lohela M; Heloterä H; Tammela T; Benjamin LE; Ylä-Herttuala S; Leow CC; Koh GY; Alitalo K
J Natl Cancer Inst; 2012 Mar; 104(6):461-75. PubMed ID: 22343031
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
